Metraipolis › archive › dc_1ada360b29cf

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced… — Europe PMC PMID:41563650

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41563650
DOI
10.1007/s10147-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-06T15:25:38.899Z
SHA-256 of the archived text
d3ead672cf7b144e31f4db5f00ae2da5b274759638bd7d7626f9312718bca36b
Stable URL of this page
https://metraipolis.com/documento/dc_1ada360b29cf

How to cite

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced… — Europe PMC PMID:41563650 — Europe PMC (en), https://europepmc.org/article/MED/41563650 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1ada360b29cf (Metraipolis archive dc_1ada360b29cf, sha256 d3ead672cf7b144e31f4db5f00ae2da5b274759638bd7d7626f9312718bca36b)
BibTeX
@misc{dc1ada360b29cf,
  title = {Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced… — Europe PMC PMID:41563650},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41563650},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1ada360b29cf; sha256 d3ead672cf7b144e31f4db5f00ae2da5b274759638bd7d7626f9312718bca36b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41563650. Agents can read the archived copy with the MCP tool read_document.